ABSTRACT. Beckerman H, Becher J, Lankhorst GJ, Ver beek ALM. Walking ability of stroke patients: efficacy of tibial nerve blocking and a polypropylene ankle-foot orthosis. Arch
Objective: To investigate the efficacy of tibial nerve blocking by percutaneous radiofrequency thermocoagulation and an ankle-foot orthosis on the walking ability of stroke patients with a spastic equinus or equinovarus foot.
Design: A placebo-controlled randomized clinical trial with a 2 X 2 factorial design and with a 3-month follow-up.
Setting: Outpatient clinic of a department of rehabilitation medicine.
Subjects: Sixty stroke patients (17 women, 43 men) with a median age of 58 years and a median period of 34 months poststroke were allocated to one of four treatment groups.
M ain Outcome M easures: Changes in walking ability (mea sured with the Sickness Impact Profile category " ambulation possible score range, 0% to 100%) and walking speed after 3 months.
Results: With respect to walking ability, the efficacy of ther mocoagulation as compared with placebo thermocoagulation was .56% (95% confidence interval [Cl] -3.01% to 4.13%), whereas the efficacy of the ankle-foot orthosis as compared with the placebo ankle-foot orthosis was 2.72% (95% Cl -.94% to 6.38%). To study the potential synergistic effect of both treatments, a multivariate model was used; interaction between both treatments was small, .83% (95% Cl -6.73% to 8.40%). Analysis restricted to the compilers (n = 30) showed an in creased efficacy of thermocoagulation and a decreased efficacy of the ankle-foot orthosis. The changes in comfortable and max imal safe walking speed were less than .lOm/sec and were nei ther clinically nor statistically significant (the median baseline values for the total group were .42m/sec and .56m/sec, respec tively).
Conclusion: No support was found for the beneficial effects of either thermocoagulation of the tibial nerve or a polypropyl ene ankle-foot orthosis in 5 degrees of dorsiflexion on the walk ing ability of stroke patients.
o
f Rehabilitation Medic of Physical Medicine tation
ERCUTANEOUS radiofrequency thermocoagulation is a current treatment method in the management of intractable pain. Dorsal spinal roots (rhizotomy) as well as cranial nerves are blocked for control of chronic pain or trigeminal neuralgia. Percutaneous radiofrequency rhizotomy has also been shown to be an effective means of controlling generalized spasticity.1 '6 In 1987 the first clinical results were published on thermocoagu lation of peripheral nerves (obturator and tibial nerve).7 An 11-year-old cerebral palsied boy with spasticity of the femoral adductors and gastrocnemius muscles was treated successfully. Two uncontrolled studies followed: Arendzen8 in 1989 investi gated the effects of thermocoagulation of the tibial nerve in 14 ambulatory stroke patients, and Herz et al6 in 1990 described the clinical results of sciatic nerve blocking in 32 nonambulatory patients. Percutaneous radiofrequency thermocoagulation of pe ripheral nerves is used for the relief of local spasticity as an alternative to chemical nerve blocks with phenol. It has been hypothesized that radiofrequency thermocoagulation would be more effective, especially in patients with severe spasticity. Furthermore, the duration of effects would be longer and the number of side effects (painful paresthesias) would be smaller, since no chemical agent is involved.
We present here the results of a placebo-controlled random ized clinical trial of the efficacy of thermocoagulation of the tibial nerve and an ankle-foot orthosis (AFO) on the walking ability of stroke patients with a spastic equinus or equinovarus foot. After the first 6 months of rehabilitation, approximately 80% of stroke patients are able to walk independently, with or without using a walking aid.9,1" Nevertheless, many of these patients are still disabled with regard to mobility.11 This disabil ity is usually associated with a strong synergistic extension pattern in the lower limb, resulting in an equinus or equinovarus position of the foot during walking.1* In these patients, tibial nerve blocking by phenol or percutaneous radiofrequency ther mocoagulation is used to reduce spasticity of the calf muscles. A second option is to inhibit the spastic position of the foot using an ankle-foot orthosis (eg, a polypropylene AFO in a 5° dorsiflexion position). An AFO in a 5° dorsiflexion position also stimulates normal walking (ie, heel strike and foot unrolling).
Neither the efficacy of the separate treatments (ie, thermoco agulation of the tibial nerve and an AFO) nor the efficacy of the combined treatment on walking ability has previously been the subject of a randomized clinical trial. Although thermocoag ulation as well as ankle-foot orthoses improve gait parameters such as stride length, stance symmetry, and heel-contact time in hemiplegic patients,81-1,14 the question is whether they improve walking ability as measured with the Sickness Impact Profile category " ambulation" , which is a self-assessment health status measure.15
PATIENTS AND METHODS

Study Design
A placebo-controlled randomized clinical trial with a 2 X 2 factorial design was performed. The randomized clinical trial is generally considered to be the best design for intervention Arch Phys M ed Rehabil Vol 77, Novem ber 1996 e f f i c a c y o f t ib ia l n e r v e b l o c k i n g A N D AFO, Beckerman 1145 studies, with minimal threats to validity.1617 A factorial design is one in which two or more experimental treatments are studied simultaneously. The general features of a 2 X 2 factorial design are two treatment arms with two conditions of each treatment, resulting in 4 possible combinations.18 A factorial design offers the opportunity to investigate whether any combinations of treatments are particularly effective or notably ineffective.1618 Randomization was carried out with sealed envelopes, prepared in advance by an independent statistician, using random per muted blocks.
Subjects
Stroke patients with walking problems caused by a spastic equinus or equinovarus position of the foot were eligible for the trial if they were between 18 and 75 years of age and had suffered a first ischemic or hemorrhagic stroke of a cerebral hemisphere resulting in hemiplegia. At least 4 months had to have elapsed between the cerebrovascular accident and partici pation to prevent confounding of the study results by initial recovery (the natural course).19 Sufficient communication and cognition abilities and a satisfactory general condition were required for full cooperation in the trial. To ensure blinding of the participants, patients treated previously by thermocoagula tion were excluded. Furthermore, a " wash-out" period of at least 3 months was required if patients had been treated with phenol prior to participation. Patients were excluded if they met one or more of the following exclusion criteria: more than one stroke; brain stem infarction; unable to walk independently; neurologic, orthopedic, or vascular disorders negatively influ encing ambulatory activities. Exclusion criteria also included structural shortening o f the soleus muscle and/or gastrocnemius muscle, skin lesions, or foot deformities, since they preclude the proper fitting of an AFO.
Before randomization, each patient received a nerve block with a local anesthetic (bupivacainechloride 0.5%), intended especially to diagnose those patients whose standing and walk ing ability was largely dependent on extensor spasticity. The diagnostic block only acts temporarily; the anesthetic effect fully disappears within 7 to 12 hours after the injection. In five patients this diagnostic nerve block had a temporary disabling effect on standing or walking; they were excluded from the trial. Sixty patients giving written informed consent were ran domized to one of four groups in accordance with the 2 X 2 factorial design.
Thermocoagulation Arm
For thermocoagulation (TH) the tibial nerve was identified in the popliteal fossa, using transcutaneous stimulation. After anesthetizing the skin, a needle was placed into the tibial nerve. With low frequency stimulation, the nerve fibers innervating the spastic muscles that most hampered the patient's gait (eg, soleus muscle, gastrocnemius muscle, tibial posterior muscle, or toe flexors) were further localized and anesthetized (5 cc lidocainechloride 2%). Subsequently, these fibers were heatinjured with radiofrequency energy (300kHz, Model RFG 3b Lesion Generator'1). The temperature was brought to 80°C within 40 seconds and was held constant for the next 60 seconds. This procedure was repeated twice after a slight change of position of the needle within the nerve. This treatment protocol has already been proven clinically useful. 8 The second treatment condition consisted of placebo thermocoagulation (PTH). The treatment protocol was similar, including the anesthetizing of the tibial nerve; however, radiofrequency energy output was zero.
Ankle-Foot Orthosis (AFO)Arm
After the nerve blocking procedure, a polypropylene AFO was custom-made for each patient. The AFO under investigation consisted of a polypropylene AFO in 5° dorsiflexion, corrected for shoe heel height. This AFO has been designed to prevent an equinus or equinovarus position of the foot during walking and inhibit the synergistic extension pattern.20 During the stance phase only a minimal dorsiflexion is possible, caused by the transformation of the material. On the contrary, plantar flexion is impossible. The placebo AFO (PAFO) consists of a polyproi pylene hinged AFO that allows normal range of motion of dorsiflexion and plantar flexion. Varus and valgus positioning of the foot is corrected by both AFOs.
Outcome Measures
»
In this trial, walking ability was used as primary outcome measure. Walking means " progressing on foot" , whereas abil ity means " to perform an activity in the manner or within the range considered normal for a human being." 21 Actual walking ability was measured with the Sickness Impact Profile (SIP), a self-assessment measure of health-related dysfunctions, which has been validated for the Dutch language.22,21 The SIP covers 12 different categories of disabilities, using 136 yes/no state ments, and gives a weighted score to each statement (see appen dix). Furthermore, a physical dimension score (based on 3 cate gories) and a psychosocial dimension score (based on 4 categories) can be calculated. The scale values (weights) for each item answered affirmatively are added. The sum is divided by the maximum possible dysfunction score for that category, multiplied by 100. Potential scores range from 0% to 100%, with higher percentages representing greater ' 'sickness impact' ' and, thus, poorer health. 15 We used the category " ambulation" (12 items), or more specifically the change from baseline score, as the primary outcome measure (see appendix).
A secondary outcome measure concerns walking speed. The patients walked on an 11 -m walkway at a comfortable and safe maximum speed while wearing, respectively, shoes, orthosis, and walking device. Patients were instructed to walk to the other side of the . human movement laboratory at their normal speed and as fast as judged safely by themselves. The velocity was automatically measured with two infrared beams over a distance of 5.5m. In addition, muscle function impairments, including the motor function of the lower extremity, sitting and standing balance, spasticity, ankle clonus, muscle tone, and Achilles tendon reflex,24 as well as satisfaction, compliance, and side effects were assessed by clinical examination or by questionnaire.
All measurements took place at baseline and 12 weeks after fitting the orthosis.
15
Blinding
The patients were treated by one physiatrist and an orthotist. The physiatrist was unblinded, whereas the orthotist was only blinded to the nerve blocking part of the trial; neither was involved with the measurements. Baseline measurements and follow-up measurements were conducted by two evaluators who were also blinded to the nerve block. The patients were blinded or at least naive to both the peripheral nerve block as well as the AFO. Success of patient blinding was checked by asking patients at the final follow-up which treatments they thought they had received.
Statistical Analyses
The efficacy of thermocoagulation and the AFO was exam ined both without and with statistical controls for confounding
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variables. First, lor walking ability and walking speed the groups were compared on their median change scores at 3-month follow-up. The proper use of randomization only guaran tees that there is no bias in the selection of patients for the different treatment groups. However, it provides no guarantee for baseline similarity of the treatment groups. Therefore, multi ple linear regression analyses were additionally used to estimate group differences adjusted for differences at the baseline for important prognostic factors, and to enlarge the precision of the point estimates of the treatment effects (ie, smaller 95% confidence intervals of the regression coefficients). The term " treatment effects" is used to indicate the adjusted differences in change scores between groups with respect to walking ability and walking speed, respectively, to estimate the efficacy of thermocoagulation and the AFO. Age, time since stroke, hemineglect, thalamic (pain) syndrome, ankle clonus, postural reflex activity, quadriceps strength, and paramedical cointerventions were a priori defined as prognostically important. Nevertheless, making allowance for our sample size and to prevent so-called " overfitting" of the data, the regression model was limited to the three prognostic factors with the highest p values.25,26 These three factors were selected with backward regression analysis. The analyses were carried out with SPSS-PC+ version 4.01.b
To measure the impact of the compliance of the (P)AFO on the study results, we also performed a " complier analysis." This analysis was restricted to patients who stated that they had worn the orthosis every day or nearly every day. This was verified by the clinician's report at the follow-up visits. Immediately after the procedure, the technical performance of the thermocoagulation in a few patients was qualified as " probably not perfect." These patients were also excluded from the " complier analysis.
RESULTS
Study Population
Between August 1992 and May 1994, 60 stroke patients were enrolled in the trial. Seventeen women and 43 men with a median age of 58 years (range, 21 to 72 years) and with a median time since stroke of 34 months (range, 5 to 185 months) were randomly allocated to one of four treatment groups: group 1, TH/AFO; group 2, PTH/AFO; group 3, TH/P AFO; group 4, PTH/PAFO. Table 1 shows the extent of baseline similarity of the four groups with respect to demographic and clinical characteristics. There were some essential differences between the four groups at baseline. Group 4, the double-placebo group, had the highest median age (60.5 years) and the shortest median period poststroke (2 years), and more left-sided than right-sided hemiplegic subjects, but at baseline also had poorer scores on the outcome measures (table 2) .
Three patients withdrew from the trial. Reasons for with drawal were unknown in 2 cases (both group 2), whereas one patient (group 4) was disappointed with the treatment results and refused further cooperation. Table 3 shows the crude (ie, not adjusted for baseline differ ences) median improvement on the main outcome measures for each group separately. For each patient, all follow-up measure ments took place 12 weeks after fitting the orthosis, that is, 14 weeks after the nerve blocking procedure. Groups 1 and 2, unlike groups 3 and 4, showed a small improvement on all outcome measures. The magnitude of the adjusted group differences, represent ing the treatment effects, and the 95 % confidence intervals (Cl) , are presented in table 4. These estimates are adjusted for differ ences between the groups at baseline with respect to age (years), period poststroke (months), and quadriceps strength (normal/ decreased). This linear regression model explained 17% of the variation in change scores of walking ability. The small change in " sickness impact" on ambulation casts doubt on the clinical significance of the efficacy of both thermocoagulation and the AFO. Figure 1 presents the cumulative distributions of the pro portion of improved patients per treatment group. On the ab scissa, scores of more than 0 indicate an improvement of the walking ability as measured with the SIP. If one chooses a score on the abscissa, one can read on the ordinate the proportion of patients of the four treatment groups with at least that score. The curves of groups 1 and 2 (both with the AFO) are almost identical, and are favorable (higher) as compared with the curves of groups 3 and 4 (both with the PAFO), respectively. 
Walking Ability
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In groups l and 2 nearly all patients improve, whereas in the other two groups less than half of the patients improve.
The results on walking speed (in meters per second) are not completely consistent with the results on SIP ambulation (table  4) . (Pearson's correlation coefficient between change in SIP score and change in comfortable walking speed r = .20 with one-tailed p = .07). Nevertheless, they lead to a similar conclu sion. A small and clinically irrelevant improvement of comfort able walking speed as well as maximal safe walking speed could only be demonstrated in the ankle-foot orthosis group as compared with the placebo orthosis group.
Compiler Analysis
Twenty-eight patients did not achieve optimal compliance with respect to the (placebo) AFO. In two additional cases the thermocoagulation was not perfect from a technical point of view. A compiler analysis was done on the patients who com plied well (n = 30; group sizes: 6, 13, 5, and 6, respectively). Table 5 presents the results of the complier analysis together with the results of the full analysis, using the same linear regres sion model. In this table, the results are averaged for each treatment irrespective of the second treatment (ie, the small interaction effects are ignored). With respect to walking ability (SIP ambulation), the efficacy of thermocoagulation increases in the complier population: 4.28% as compared to .56% in the full study population. On the other hand, the efficacy of the ankle-foot orthosis decreases (-1.69% for the compliers and 2.72% in the total group). With respect to walking speed, the differences between the compliers and the full analysis are small, with a maximum of .06m/sec.
Adverse Effects
Twenty patients had at least one complaint about the active (n = 11) or inactive thermocoagulation (/i = 9), whereas 44 patients had one or more complaints about their custom-made AFO (n = 21) or PAFO (n = 23). Efforts were made to solve each problem as soon as possible.
With respect to the nerve block three categories of complaints could be distinguished: (1) local problems caused by the injec tion itself (n = 4); (2) neurological problems or problems related to the autonomic nervous system; the most severe problems were reflex sympathetic dystrophy (n = 1) and extended neural gia (1 treated with TH, and 1 treated with PTH). Other minor Effects adjusted for baseline differences with respect to age, period poststroke, and quadriceps strength. Positive signs indicate improvement from the baseline; negative signs indicate a decline from the baseline scores. complaints were temporary burning sensations of the foot and muscle fibrillations, especially at night; (3) problems related to biomechanical changes, such as a stiff knee or leg, muscle pain or muscle cramp, instability of the ankle, and dropping of the foot during walking (fig 2) . Both neurological as well as biome chanical problems were more prevalent in the thermocoagula tion group (23.3% of the patients). However, 13.3% and 16.7% of the placebo-treated patients also had neurological or biome chanical complaints, respectively, thought to be associated with placebo thermocoagulation. With respect to the orthoses, problems were related to (1) range of motion (ROM) of the (P)AFO. In case of the active AFO, the foot is forced in 5° dorsifiexion. This results in a continuous stretching of the calf muscles, which was sometimes experienced as unpleasant. Furthermore, it results in a knee flexion during gait (stance-phase) and standing. With respect to the PAFO there is a free range of motion. The patient is stimu lated to actively dorsiflex his foot or raise his knee; otherwise he will stumble over his foot or experience other problems during walking. (2) Walking. (3) Shoes: although the polypropylene (P)AFO is only a few millimeters thick, nearly a quarter of the patients complained about wounds on the toes, toe clawing, or burning feelings of the foot. New shoes with a broad instep, and mostly one size larger than normal, solved this problem. (4) Fitting of the (P)AFO: both orthoses caused a number of prob lems concerning the fitting of the orthosis (32.2% in the AFO group and 30% in the PAFO group). (5) Handling of the (P)AFO and/or the material: sweaty foot and calf, metal allergy, and problems caused by the instep fixation bandage. Some patients were no longer able to put on their shoe and (P)AFO unaided (fig 3) . Problems related to walking, the shoes, and the material were slightly more common among the PAFO group, whereas problems related to ROM were more common in the AFO group.
DISCUSSION
To our knowledge, this was the first randomized clinical trial of the effects of thermocoagulation and a polypropylene AFO on the walking ability of stroke patients. Even for phenolizadon of the tibial nerve, a well-known nerve blocking procedure with the same therapeutic intention, no randomized clinical trials have been conducted until now.27 Our clinical trial shows that the efficacy of both therapeutic interventions appeai-s to be nei ther statistically significant nor clinically relevant, despite the thermocoagulation performed by a highly skilled physiatrist and the AFO fitted by an experienced orthotist. The high noncompliance (50%), even in the group with two active treatments, was already an indicator of the disappointing results after 3 months. The objective results, however, accord with the lack of satisfaction of the patients with the treatment results. Only 17% of the patients were satisfied, 38% were dissatisfied, with 42% being neither. At the end of the followup period, each patient was also asked to guess which treatments he/she had received, and to indicate his/her degree of certainty about these guesses on a seven-point scale (table 6 ). In the active thermocoagulation groups, the number of incorrect guesses exceeded the number of correct ones, whereas the oppo site held for the placebo thermocoagulation groups. In our opin ion these results also express the patients' disappointment about the results of the active thermocoagulation, rather than any un masking of the placebo thermocoagulation. The higher mean certainty scores of the incorrect guesses support this argument. Concerning the ankle-foot orthosis, the percentage of correct guesses in the total AFO group was rather high. In the PAFO with their spasticity removed, would achieve a better fit for group the percentages of correct and incorrect guesses were their orthoses. This could not be confirmed by our compliance For thermocoagulation, patients were asked, "Which nerve block do you think you received, the real nerve block or the placebo?'' For ankle-foot orthosis, "Which AFO do you think you received, the real one or the placebo?" Mean certainty score presented (0 = absolutely unsure about the answer; 6 = absolutely sure about the answer). Abbreviations: As in table 1.
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nearly equal. The patients with a PAFO were the most certain about their correct choice.
data and also was not observed by the orthotist. Noncompliers mostly used their old orthoses again. This means that in the full Compliance to the assigned treatment is of particular imporanalysis the contrast between the groups was biased by the old tance. A " pragmatic" analysis of the total study population, disregarding noncompliance, may result in an underestimation orthoses, whereas in the complier analysis the original experi mental contrast persisted (AFO vs PAFO). Furthermore, as both of the true treatment effects. With an " explanatory" approach experimental orthoses limit varus and valgus positioning of the confined to compliance data only, one hopes to come nearer to foot, the positive effects seen in the full analysis and not in the the truth, which is an estimation of the efficacy of a treatment complier analysis could be due to this stabilizing function. under optimal circumstances, including fully compliant patients. On the other hand, with the advantages and disadvantages of a treatment, and taking the degree of patient compliance into account, the " pragmatic" approach provides an estimation of the effects that are best related to actual clinical practice,16 because patient populations in clinical practice consist of a mix of more or less compliant patients.
It is difficult to explain the differences found between both analyses with respect to walking ability. A potential problem of a factorial design is that noncompliance over one therapeutic contrast, given that the efficacy of that intervention depends on compliance, also affects a valid comparison of the other therapeutic contrast and vice versa. 28 The increased efficacy of thermocoagulation, irrespective of the AFO used, is hard to Using a factorial design has specific implications for group sizes. The sample size calculation was initially based on the assumption that a reduction of one item or 8% of the SEP " am bulation' ' score, taking the baseline value into account, would constitute a clinically important difference between the groups. When the focus is on the two separate main effects of the treatments, nine patients per group, that is, 36 patients in total, were needed to obtain a study power of 90% (5% significance; one-sided test). However, demonstrating a significant interac tion effect between thermocoagulation and the AFO with the same power would require four times the total sample size.29 Therefore, with our sample size there is an increased risk of a false negative interaction effect.
In chronically disabled people, therapeutic effects tend to be explain. Compliance could have been induced by the good remodest, especially when they are measured in behavioral terms, suits of thermocoagulation. However, patients receiving placebo using health status instruments. Nevertheless, as health status thermocoagulation were more compliant. With respect to the instruments such as the SIP are increasingly used, information (P)AFO, one might expect that the thermocoagulated patients, With respect to walking speed there is more information available. Normal walking speed varies between 1.39m/sec in men between the ages of 20 and 89 years33 and 1.29m/sec in women (20 to 70 years).34 Healthy men beyond the age of 60 still have a walking speed of 1.18m/sec and are able to increase their speed to at least 1.60m/sec.33 Normal walking speed in healthy women 64 years of age and older is .96m/sec (SD .23m/ sec).35 These elderly women were able to increase their speed to 1.42m/sec (SD .30m/sec). To function independently within aterial the community, stroke patients must walk at velocities much greater than measured in our study. The median comfortable and maximal safe walking speeds of our study population at baseline were .42m/sec and .56m/sec, respectively, whereas the
Arch Phys Med Rehabil Voi 77, November 1996 EFFICACY OF TIBIAL N ERVE BLOCKING AND AFO, Beckerman
adjusted changes were less than .10m/sec (EffectAW ) for the compliers). To cross the street safely a velocity of .74m/sec in rural towns, .98m/sec in small towns, and 1.06m/sec in cities seems minimally necessary in the USA. 16 The Swedish norm of 1.4m/sec necessary to negotiate traffic-light-controlled inter sections safely is even higher,17 and even most of the healthy population should increase their normal walking speed. To find a sufficient number of patients we used many sources of patient recruitment. Altogether, this resulted in a severely and chronically disabled study population. We were impressed by the enormous problems these chronic stroke patients encoun ter daily. A 5-year follow-up study showed that functional capa bilities after stroke, including walking, are not stable, but de cline further.1 1 5 The search for effective treatment possibilities to improve walking abilities, therefore, remains urgent. Moreover, because the reduction of spasticity and use of an orthosis (and try-outs) are seen as especially important during early rehabilita tion a few weeks after the cerebrovascular accident, it still re mains interesting to investigate the potential benefits of thermo coagulation combined with the polypropylene ankle-foot orthosis during early rehabilitation. Although noncompliance in the placebo AFO groups was higher than in the AFO groups, both orthoses caused problems. From a pragmatic point of view, there is much room left for further improvement of the AFO. The fitting of a polypropylene AFO is an accurate and timeconsuming process and demands much attention from both the orthotist and the physiatrist. Our findings underline the impor tance of continued careful monitoring of the suitability of the AFO at regular intervals in order to guarantee an optimal fitting.
The question may be raised if the lack of effect is an inevita ble result of a heterogeneous stroke population. However, they formed a homogeneous group with regard their spastic equinus position of the foot. The design of the trial was such that if the experimental treatments had any pronounced effect on walking ability, we would have been able to detect this effect. Moreover, the diagnostic nerve block and subsequent exclusion from the trial of patients whose walking ability declined afterwards in sured that only those expected to improve were randomized. So, a priori we tried to select a homogeneous group of patients with spastic foot problems who were likely to respond to the experimental therapy. In conclusion, the lack of effect of this study is not the result of studying this heterogeneous group of stroke patients; rather, it is simply because both thermocoagula tion and the ankle-foot orthosis lack a pronounced effect on the walking ability of stroke patients.
